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Ethics The study was approved by an ethics 
committee and all patients provided written 
informed consent.
Results and discussion All the study patients 
had HTx performed using the Lower–Shumway 
technique after a mean (SD) number of 256 (140) 
days of being put on the waiting list for trans‑
plant. The mean (SD) cold ischemia time was 218 
(38) minutes, and the mean (SD) cross ‑clamping 
time was 181 (30) minutes. There was no periop‑
erative death in the study group.
Non–vitamin K oral anticoagulants Two men 
with chronic atrial fibrillation, the first (36 
years) diagnosed with ischemic cardiomyopa‑
thy and the second (48 years) with dilated cardio‑
myopathy, were transferred into the operation 
room 22 and 18 hours after receiving the last 
dose of dabigatran, respectively. Owing to a rel‑
atively short half ‑time of dabigatran elimina‑
tion in the plasma (7 to 9 hours), we decided 
not to administer a reversal agent. A 43‑year‑
‑old patient with dilated cardiomyopathy and 
atrial fibrillation received 5 g of idarucizumab 
(Praxbind, Boehringer Ingelheim Pharma, In‑
gelheim, Germany). The mean postoperative 
drainage volume in those men was 634 ml and 
579 ml, respectively. Neither pericardial nor 
pleural fluids were detected during the postop‑
erative hospital stay.
Oral anticoagulants (warfarin) There were 5 pa‑
tients (25%) treated with warfarin: 3 (15%) with 
a mechanical valve prosthesis and 2 (10%) re‑
ceiving mechanical paracorporeal circulato‑
ry support.
Introduction Patients with congestive heart 
failure are at high risk of death and 1.4% to 
2.4% annual risk of stroke. The latter substan‑
tially increases with atrial fibrillation and oth‑
er risk factors included in the CHA2DS2‑VASc 
score.1 ‑3 Nowadays, non–vitamin K antago‑
nist oral anticoagulants (NOACs) are the rec‑
ommended drug class in this population.4 
Their major disadvantage is the immediate 
reversal of the antithrombotic effect in ur‑
gent surgery.
We present a single ‑center approach to an‑
tithrombotic and antiplatelet therapy in pa‑
tients awaiting and undergoing heart trans‑
plant (HTx).
Methods Between the years 2017 and 2019, 
84 patients were put on a waiting list for HTx 
in our Department of Cardiac Surgery and 
Transplantology. Twenty of them (17 men and 
3 women; mean [SD] age, 44 [13] years) under‑
went HTx. They were referred for this proce‑
dure because of dilated (10 [50%]), ischemic (9 
[45%]), and hypertrophic (1 [5%]) cardiomyopa‑
thy. Three patients (15%) were treated with dab‑
igatran for chronic atrial fibrillation; the mean 
CHA2DS2‑VASc score was 2.3, and the mean 
HAS ‑BLED score was 1.3. In the study group, 
there was no history of major bleeding, end‑
‑stage kidney disease (mean [SD] serum creat‑
inine level, 156 [43] µmol/l), or liver dysfunc‑
tion (mean [SD] aspartate aminotransferase 
level, 56 [13] IU/l).
Statistical analysis Data were entered and anal‑
ysed using the Statview 5.0 software (SAS Insti‑
tute, Inc., Cary, North Carolina, United States).
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daily, which was initiated within 5 days after 
surgery. None of the patients required antico‑
agulation therapy. No bleeding complications 
were observed. We did not observe any differ‑
ences between patient groups in terms of pro‑
cedural complications.
Within the first postoperative year, patients 
were treated with standard triple immunosup‑
pressive therapy including an calcineurin inhib‑
itor, mycophenolate mofetil, and oral steroids.
Our study was a single ‑center analysis of an‑
tithrombotic regimens used in patients await‑
ing HTx. Patients qualified for HTx most of‑
ten require oral anticoagulation or antiplate‑
let treatment.5 Generally, both kinds of thera‑
py should be interrupted in a planned manner 
before most of surgical procedures. However, 
HTx is performed on an urgent basis. Therefore, 
an optimal strategy of anticoagulation reversal 
should be implemented in the operating center 
in advance. The interruption of pharmacother‑
apy may increase the risk of either bleeding or 
thromboembolic events. These complications 
may be, however, related not only to drugs but 
also to preoperative factors, including kidney 
function or the EuroSCORE.6
Similar to coronary artery bypass grafting,7 
there is no need for aspirin withdrawal before 
HTx.
Warfarin therapy is still the first ‑choice treat‑
ment in many patients, including those with left 
ventricular assist device.8 A 4‑factor prothrom‑
bin complex concentrate is a useful drug for war‑
farin reversal, which, compared with fresh fro‑
zen plasma, may prevent volume overload and 
is recommended in clinical practice.9
There is currently an increasing number of 
patients on long ‑term NOAC therapy.10 Discon‑
tinuation of each drug relates to its half ‑life, pa‑
tients’ kidney function and age, and is relatively 
Patients with a mechanical valve prosthe‑
sis treated with warfarin within the therapeu‑
tic range of the international normalized ratio 
(INR) on admission were transferred into the op‑
eration room without INR correction. The mean 
(SD) cold ischemia time was 238 (14) minutes. 
After protamine administration, the standard 
protocol of fresh frozen plasma and platelet con‑
centrate infusion was augmented by prothrom‑
bin complex concentrate administration if need‑
ed. The mean (SD) postoperative drainage vol‑
ume in this patient subgroup was 712 (53) ml 
(TAble 1).
One patient developed heparin‑induced 
thrombocytopenia after 2 weeks of unfraction‑
ated heparin infusion during intra ‑aortic bal‑
loon pump treatment before HTx, which was 
diagnosed based on a platelet count decrease 
from 361 to 64 × 103/mm3. The patient had no 
thrombotic complications and was subsequent‑
ly treated with bivalirudin infusion before and 
during surgery. After 1 week, the patient’s plate‑
let count increased to 153 × 103/mm3. The bivali‑
rudin infusion was adjusted following the acti‑
vated clotting time.
Low ‑molecular ‑weight heparin Seven patients 
were treated with low ‑molecular ‑weight heparin. 
The therapy was not withdrawn prior to surgery 
due to its urgency. The mean (SD) postoperative 
drainage volume was 710 (145) ml.
Aspirin Five patients were receiving acetylsal‑
icylic acid before HTx, as they were diagnosed 
with ischemic heart disease. The mean (SD) post‑
operative drainage volume in these patients was 
690 (123) ml.
All study patients were treated with low‑
‑molecular ‑weight heparin during hospitaliza‑
tion and acetylsalicylic acid at a dose of 75 mg 









bivalirudin (n = 7)
INR before HTx 2.8 (0.2) 1.1 (0.1) 1.1 (0.15) 1.1 (0.13)
Blood products required 
per patient, units
FFP 8 (2) 8 (2) 10 (2) 8 (3)
Platelets 10 10 10 10
Postoperative drainage volume, ml 712 (53) 579; 634; 538a 690 (123) 710 (145)
PCC per patient, units 4 (2) – – –
Patients receiving idarucizumab (2.5 g 
twice daily)
– 1 – –
Patients not receiving idarucizumab – 2 – –
Data are presented as number or mean (SD).
a Drainage volumes of 3 study patients
Abbreviations: FFP, fresh frozen plasma; HTx, heart transplant; INR, international normalized ratio; LMWH, low ‑molecular ‑weight 
heparin; NOAC, non–vitamin K antagonist oral anticoagulant; PCC, prothrombin complex concentrate
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safe for approximately 2 half ‑lives of the drug 
prior to a surgical intervention.9 Postponing 
surgery seems to be reasonable in most cases, 
but it is impossible in solid organ transplant. 
Therefore, a reversal agent, currently available 
for dabigatran, enables prompt patient prepa‑
ration before HTx.11
Considering the availability of idarucizumab, 
the recommendations in our institution were 
altered for patients awaiting HTx, indicating 
the need for dabigatran use.
There is still lack of clear guidelines in the field 
of the  antithrombotic regimen before HTx. 
Therefore, we believe that they should be im‑
plemented to increase patient safety. We com‑
pared complication rates in our study subgroups 
and did not find any significant differences in 
the postoperative drainage volumes and bleed‑
ing events. However, our observations are lim‑
ited by the small number of patients included in 
the study. Nevertheless, the availability of a re‑
versal agent is crucial when performing urgent 
surgery including HTx and, therefore, we encour‑
age the use of dabigatran in the pre ‑HTx period.
Conclusions The antithrombotic regimens are 
particularly problematic in urgent cardiac sur‑
gery. The reversibility of NOAC activity using its 
specific antidote should be considered a possible 
and safe option in HTx procedures.
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